Scientific and Clinical Studies
Theralac® Probiotic Strains

Scientific and Clinical Studies

Theralac® Probiotic Strains

Lactobacillus paracasei strain F-19 present in Theralac® at 5 Billion CFU Per Capsule

References:

Deposited at the American Type Culture Collection (ATCC) as SD5275.

Engelbrektson, A.L., Korzenik, J.R., Sanders, M.E., Clement,
B.G., Leyer, G., Klaenhammer, T.R. and Kitts, C.L. (2006). Analysis of
treatment effects on the microbial ecology of the human intestine. FEMS
Microbiol. Ecol. 57:239-250

Paineau, D., Carcano, D., Leyer, G., Darquy, S., Alyanakian,
M.A., Simoneau, G., Bergmann, J.F., Brassart, D., Bornet, F. and Ouwehand, A.C.
(2008). Effects of seven potential probiotic strains on specific immune
responses in healthy adults: a double-blind, randomized, controlled trial. FEMS
Immunology & Medical Microbiology 53(1):107-113

Roessler, A. (nee Klein), Friedrich, U., Vogelsang, H.,
Bauer, A., Kaatz, M.,Hipler, U.C., Schmidt, I.
and Jahreis, G. (2007). The immune system in healthy adults and patients with
atopic dermatitis seems to be affected differently by a probiotic intervention.
Clinical and Experimental Allergy 38:93-102.

List of taxonomic units proposed for QPS status http://www.efsa.europe.eu/EFSA/Scientific_Opinion/sc_op_ej587_gps_en.pdf.

Return to Scientific References